Pharmacokinetics and Pharmacodynamics of Cinacalcet in Hepatic Impairment Phase I, Open-Label, Parallel-Group, Single-Dose, Single-Centre Study

• Published in: Clinical drug investigation Vol. 28; no. 10; pp. 635 - 643
• Main Authors: Padhi, Desmond, Harris, Robert Z., Salfi, Margaret, Noveck, Robert J., Sullivan, John T.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.01.2008; Wolters Kluwer Health, Inc; Springer Nature B.V
• Subjects: Administration, Oral; Aged; Area Under Curve; Calcium - blood; Chromatography, High Pressure Liquid - methods; Cinacalcet Hydrochloride; Female; Half-Life; Headache - chemically induced; Humans; Immunoassay - methods; Internal Medicine; Liver - metabolism; Liver Diseases - blood; Liver Diseases - metabolism; Liver Diseases - physiopathology; Male; Mass Spectrometry - methods; Medicine; Medicine & Public Health; Metabolic Clearance Rate; Middle Aged; Naphthalenes - administration & dosage; Naphthalenes - adverse effects; Naphthalenes - pharmacokinetics; Nausea - chemically induced; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy; Chronic Kidney Disease Patient; Secondary Hyperparathyroidism; Parathyroid Carcinoma; Cinacalcet; Hepatic Impairment

Background and objective: The calcimimetic cinacalcet lowers blood parathyroid hormone (PTH), calcium and phosphorus levels and calcium-phosphorus product in patients with chronic kidney disease receiving dialysis. Cinacalcet is metabolized primarily through oxidative and conjugative pathways. Hepat...